KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Colgate Palmolive (CL) Share-based Compensation (2016 - 2025)

Colgate Palmolive (CL) has 15 years of Share-based Compensation data on record, last reported at $28.0 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 3.7% year-over-year to $28.0 million; the TTM value through Dec 2025 reached $155.0 million, up 14.81%, while the annual FY2025 figure was $155.0 million, 14.81% up from the prior year.
  • Share-based Compensation reached $28.0 million in Q4 2025 per CL's latest filing, down from $72.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $72.0 million in Q3 2025 and bottomed at $14.0 million in Q1 2023.
  • Average Share-based Compensation over 5 years is $33.6 million, with a median of $27.5 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: skyrocketed 137.5% in 2021, then plummeted 51.72% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $28.0 million in 2021, then decreased by 28.57% to $20.0 million in 2022, then grew by 25.0% to $25.0 million in 2023, then rose by 8.0% to $27.0 million in 2024, then rose by 3.7% to $28.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $28.0 million in Q4 2025, $72.0 million in Q3 2025, and $32.0 million in Q2 2025.